Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Investigators at Lanzhou University target cancer gene therapy
April 1st, 2008
According to recent research published in the journal Biotechnology and Applied Biochemistry, "Cdc42 (cell division cycle 42), a member of Rho GTPases, is involved in cell transformation, proliferation, survival, invasion and metastasis of human cancer cells. Here, RNAi (RNA interference)-mediated gene silencing was used to investigate the roles of Cdc42 and to assess its therapeutic potential in human bladder cancer." "The results showed that Cdc42 silencing resulted in a marked reduction of Cdc42 mRNA and protein expression and a significant inhibition of cell proliferation from G(0)/G(1)- to S-phase in two (E) and T24) human bladder-cancer cell lines....
Source: Cancer Weekly (2008-04-01)
|
